Sherry Shen is an Oncology physician affiliated with Memorial Sloan Kettering Cancer Center. OpenAlex indexes 63 publications with 455 citations (h-index 12); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1275 York Ave
New York, NY 100656007
Telephone
248-404-7678Provider last certified this registry record 21 Jun 2022.
Clinical trials
- A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
- Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
8 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GE HEALTHCAREProgram year20257 payments
- AstraZeneca Pharmaceuticals LPProgram year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
95.3%Aromatase Inhibitor81.6%Letrozole69%Anastrozole16%Exemestane15%Part D≥48 patientsKinase inhibitor13.7%Ibrance100%Part D<11 patientsNervous system
4.7%Gabapentinoids4.7%Pregabalin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Characterization of inavolisib-associated hyperglycemia in metastatic hormone receptor–positive (HR+) breast cancer.
Journal of Clinical Oncology
2026 - Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group
Cancer Treatment Reviews
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Valerie Rusch, MD
Memorial Sloan Kettering Cancer Center
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”